Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSIXG4)

Drug Name

TT-173 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Bleeding disorder	GA20-GA21	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tissue factor (F3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisotumab vedotin	DMF8FK3	Cervical cancer	2C77.0	Approved	[3]
ALT-836	DMGJ71F	Adult respiratory distress syndrome	CB00	Phase 2	[4]
MORAb-066	DMTUKW9	Pancreatic cancer	2C10	Phase 1	[5]
D-Pro-Phe-Arg chloromethyl ketone	DMRJQ8X	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT02012569) Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting. U.S. National Institutes of Health.
2	TETIS study: evaluation of new topical hemostatic agent TT-173 in tooth extraction. Clin Oral Investig. 2016 Jun;20(5):1055-63.
3	FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761208.
4	ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1295-303.
5	Clinical pipeline report, company report or official report of Morphotek.
6	Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80.